Topical Erythropoietin for Treatment of Scleral Necrosis

Sepehr Feizi, Mohammadhasan Alemzadeh-Ansari, Alireza Baradaran- Rafii, Hamed Esfandiari, Ahmad Kheirkhah

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Purpose: To investigate the safety and efficacy of topical erythropoietin for the treatment of scleral necrosis. Methods: This study enrolled eight consecutive patients with scleral necrosis due to previous ocular surgery, rheumatoid arthritis-associated necrotizing anterior scleritis, and thermal and chemical burns. Conventional treatments failed to heal avascular scleral lesions in all eyes. Patients were treated with topical erythropoietin (3000 IU/mL) four times a day. Results: The mean patient age was 37.6 ± 15.5 years. The interval between the development of scleral necrosis and initiation of topical erythropoietin was 25.6 ± 12.0 days. The necrotic sclera completely healed within 31.9 ± 16.9 days in all patients. The avascular lesions did not recur, and there was no evidence of side effects during the study. Conclusion: Our results showed that topical erythropoietin could be safely used to manage scleral necrosis. Randomized clinical trials are needed to further explore the efficacy of this intervention in patients with avascular scleral lesions.

Original languageEnglish (US)
Pages (from-to)1701-1706
Number of pages6
JournalOcular Immunology and Inflammation
Issue number7-8
StatePublished - 2022


  • chemical burns
  • necrotizing anterior scleritis
  • scleral necrosis
  • surgically-induced necrotizing scleritis
  • topical erythropoietin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology


Dive into the research topics of 'Topical Erythropoietin for Treatment of Scleral Necrosis'. Together they form a unique fingerprint.

Cite this